Peloton Therapeutics is a clinical-stage drug discovery and development company focused on first-in-class oral medicines for cancer and other serious conditions. Its lead development program is PT2977, a potent and selective oral HIF-2α inhibitor targeting clear cell renal cell carcinoma and other disorders. The company emphasizes translating novel scientific insights into medicines for debilitating or life‑threatening conditions and notes that HIF-2α was previously thought to be intractable using small molecules. Proceeds from the recent financing will be used to advance Peloton’s research and development pipeline, including PT2977. RA Capital highlighted support as Peloton moves toward a Phase 3 trial of PT2977 for metastatic renal cell carcinoma and advances development in Von Hippel‑Lindau disease. The company issued the announcement from Dallas. Peloton Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule cancer therapies. Its lead programs are inhibitors of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in kidney and other cancers. The company emphasizes first-in-class approaches that target unexploited molecular vulnerabilities. Peloton is advancing these programs through clinical development with the aim of impacting renal and other oncology indications. Financially, Peloton recently completed a Series D financing, increasing proceeds to support its programs. The company is publicly identified in the article as based in Dallas. Peloton Therapeutics is a clinical-stage biotech focused on discovering and developing first-in-class small-molecule cancer therapies. Its lead program, PT2385, is a first-in-class small molecule antagonist of hypoxia-inducible factor-2α (HIF-2α). PT2385 has generated reported responses in patients with renal cell carcinoma and is being considered for applications in von Hippel-Lindau disease, glioblastoma multiforme, and other high-unmet-need diseases. The company intends to advance its HIF-2α program and other research programs toward clinical goals. Peloton completed a $52.4 million Series D private financing to support these development plans. Management stated the financing positions the company to realize the full potential of its HIF-2α antagonists and continue its research efforts. Peloton Therapeutics is a Dallas-based early-stage cancer drug discovery and development company focused on small-molecule therapeutics. It is advancing a pipeline of several small molecule-based programs, each with distinct targets and mechanisms of action, in close collaboration with scientists at UT Southwestern. The company was founded by scientist Steven L. McKnight, Ph.D., and its board includes Nobel Laureate Michael S. Brown, John W. Creecy, David V. Goeddel, Tim Kutzkey and Brett A. Ringle. John A. Josey, Ph.D., former Vice President of Discovery Chemistry at Array BioPharma, will join Peloton as President and Chief Scientific Officer. Peloton completed an $18M Series A financing led by The Column Group, with participation from Remeditex Ventures and Peter O’Donnell, Jr. This Series A supplements an $11M grant recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

Total raised

$243M

Funding rounds

4

Latest round

Series E

Latest activity

Feb 2019